These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34068664)

  • 21. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal use of lenvatinib in the treatment of advanced thyroid cancer.
    Takahashi S; Kiyota N; Tahara M
    Cancers Head Neck; 2017; 2():7. PubMed ID: 31093354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
    Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Teshima M; Otsuki N; Nibu KI; Minami H
    Front Oncol; 2021; 11():638123. PubMed ID: 34307122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis.
    Yu ST; Ge JN; Luo JY; Wei ZG; Sun BH; Lei ST
    Cancer Manag Res; 2019; 11():1525-1532. PubMed ID: 30863162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
    Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
    World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in small molecule therapy for treating metastatic thyroid cancer.
    Krajewska J; Gawlik T; Jarzab B
    Expert Opin Pharmacother; 2017 Aug; 18(11):1049-1060. PubMed ID: 28602103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach.
    Giovanella L; Scappaticcio L
    Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):229-234. PubMed ID: 31271270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Otsuki N; Nibu KI; Minami H
    Head Neck; 2019 Sep; 41(9):3023-3032. PubMed ID: 31013380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.
    Worden F
    Ther Adv Med Oncol; 2014 Nov; 6(6):267-79. PubMed ID: 25364392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Tsoli M; Alexandraki KI; Spei ME; Kaltsas GA; Daskalakis K
    Horm Metab Res; 2020 Jan; 52(1):25-31. PubMed ID: 31665790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma.
    Hyogo Y; Kiyota N; Otsuki N; Goto S; Imamura Y; Chayahara N; Toyoda M; Nibu KI; Hyodo T; Hara S; Masuoka H; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Case Rep Oncol; 2018; 11(3):735-741. PubMed ID: 30519176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.
    Berdelou A; Borget I; Godbert Y; Nguyen T; Garcia ME; Chougnet CN; Ferru A; Buffet C; Chabre O; Huillard O; Leboulleux S; Schlumberger M
    Thyroid; 2018 Jan; 28(1):72-78. PubMed ID: 29048237
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
    Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
    Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.